You are here

  • Home
  • Archive
  • Volume 81, Issue 6
  • Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study

Article metrics

Article menu
Psoriatic arthritis
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study

 

Online download statistics by month:

Online download statistics by month: February 2022 to September 2024

AbstractFullPdf
Feb 2022379400115
Mar 2022975999345
Apr 2022556560106
May 2022528528180
Jun 202232432488
Jul 202225225570
Aug 202218418535
Sep 202216616558
Oct 202214114360
Nov 202212111844
Dec 202212612533
Jan 202369669649
Feb 2023919134
Mar 2023847835
Apr 2023484629
May 2023919043
Jun 2023929226
Jul 2023817942
Aug 2023423720
Sep 2023464226
Oct 2023545125
Nov 2023766626
Dec 2023726931
Jan 2024434219
Feb 2024312620
Mar 20247071102
Apr 2024575547
May 2024595526
Jun 2024686534
Jul 2024565526
Aug 2024616018
Sep 2024595551
Total572957231863